Italy new center started with iVAC 2L in Santa Maria Goeretti, Latina.
⚡️ In Italy a new center started with a protected High-Risk PCI with the successful support…
Jincy George
Clinical & Sales Support Manager
We have a mission!
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
SEE OUR
Facts & Figures
Registrations
> 45 countries approved registrations
Cases
> 100 shared cases on LinkedIn; > 200 reported cases
> 1.000 iVAC 2L sold
> 35 distributor agreements
Hospitals
> 35 hospitals use iVAC 2L on a regular base; > 7 Centers of Excellence.
Patients
> 400 patients world wide treated by iVAC 2L
Clinical evidence
> 30 publications
Indication
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
🌍 PulseCath is expanding their global footprint
Exciting news! Another milestone reached. We are proud to announce the achievement of product registration for…
First 2 iVAC 2L cases in a new center in Romania
After first successful cases in Romania, performed at “Niculae Stancioiu” Heart Institute in Cluj-Napoca, yesterday, at…
MEET OUR
Medical advisors
Clinical programme supported by leading cardiologists